- Supported exchanges /
- F /
- 7RG0.F
REGULUS THER.COMPAR DL001 (7RG0 F) stock market data APIs
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
REGULUS THER.COMPAR DL001 Financial Data Overview
| 1.46 | |
| 1.46 | |
| - | |
| 1.46 | |
| 1.46 | |
| 1.02-3.26 | |
| 94 779 K | |
| 65 466 K | |
| 0 | |
| 1.618 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
REGULUS THER.COMPAR DL001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -37 208 000
- Earnings Per Share -1.11
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get REGULUS THER.COMPAR DL001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get REGULUS THER.COMPAR DL001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
